Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00929565 · ClinicalTrials.gov registry record
Urokinase Like Plasminogen Activator Levels in Patients Undergoing Bronchoscopy
A clinical trial, sponsored by University of Oklahoma.
- Completed
- Registry status
- 10
- Enrollment target
NCT00929565: Completed study, sponsored by University of Oklahoma.
NCT00929565 is a clinical trial that has completed, run by University of Oklahoma. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00929565 has completed, sponsored by University of Oklahoma.
- COMPLETED
- Registry status
- 10 participants
- Enrollment target
Study Summary
Some of the risk factors for bleeding following bronchoscopy is having a malignancy or an immunocompromised state. The etiology of this remains uncertain. The investigators suspect that individuals with malignancy have abnormalities involving certain factors that influence the coagulation pathway. The investigators plan to measure these factors prior to and after bronchoscopy.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2009-06 |
| Est. Completion | 2011-10 |
What the finished NCT00929565 record still lists
NCT00929565 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00929565 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00929565 about?
NCT00929565 is a clinical study titled "Urokinase Like Plasminogen Activator Levels in Patients Undergoing Bronchoscopy". Some of the risk factors for bleeding following bronchoscopy is having a malignancy or an immunocompromised state. The etiology of this remains uncertain. The investigators suspect that individuals with malignancy have abnormalities involving certain factors that influence the coagulation pathway. ...
What is the current status of trial NCT00929565?
This trial is currently completed. The enrollment target is 10 participants. The study started on 2009-06. Estimated completion is 2011-10.
Who is sponsoring clinical trial NCT00929565?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia